Skip to main content

Table 2 Effect of probiotic (B. subtilis CU1) and placebo consumption on clinical outcomes of infectious diseases

From: Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study

  Whole population (N = 100) Subset of population (N = 44)
  Probiotic group (N = 50) Placebo group (N = 50) P Probiotic group (N = 22) Placebo group (N = 22) P
  Mean SD Mean SD Mean SD Mean SD
Mean number of days with CID 5.1 7.0 6.6 7.3 0.2015a 4.5 7.3 7.3 8.2 0.1101a
Mean duration of CID (d) 5.0 4.6 5.3 4.1 0.2361a 5.8 5.6 5.7 4.1 0.2361a
Mean intensity of CID 8.1 5.0 7.6 4.4 0.7400a 9.0 6.2 8.8 5.3 0.7400a
CID frequency 1.0 1.2 1.2 1.2 0.3290a 0.8 1.0 1.3 1.2 0.1117a
Subjects with at least one CID      0.4106b      0.1260b
n 29 33   11 16  
 % 58 · 0 66 · 0   50 · 0 72 · 7  
Mean number of days with RI 4.4 6.9 6.2 7.2 0.1027a 3.7 6.9 6.6 7.9 0.0818a
Mean duration of RI (d) 5.9 5.0 5.6 4.2 0.9043a 6.8 6.3 6.1 4.3 0.9325a
Mean intensity of RI 9.3 5.3 7.8 4.6 0.1428a 11.1 6.3 9.3 5.6 0.3473a
RI frequency 0.7 0.9 1.1 1.2 0.1181a 0.6 0.7 1.1 0.9 0.0323 a
Subjects with at least one RI      0.1609b      0.0701b
n 24 31   10 16  
 % 48.0 62.0   45.5 72.7  
  1. Data are presented for the whole population (N = 100) and the subset of population with biology analysis (N = 44). (Mean values and standard deviations; numbers and percentages)
  2. Statistical differences were evaluated using Wilcoxon-Mann-Whitney’s test or Savage’s test according to the asymmetry of data (a), or logistic regression model (b)